Hematocrit test devices market seen reaching $6.47B by 2030

The hematocrit test devices market is projected to grow from $4.91 billion in 2025 to $5.22 billion in 2026, with further expansion to $6.47 billion by 2030. Demand is being pushed by more blood disorders, broader diagnostic testing and faster adoption of point-of-care and home-based screening.

Why it matters: - Hematocrit test devices measure red blood cell levels, which helps clinicians diagnose and monitor anemia, blood disorders and other conditions. - Growing demand for faster diagnostics is expanding use across hospitals, laboratories, emergency care and decentralized testing settings. - The market outlook points to continued investment in diagnostic infrastructure and preventive screening.

What happened: - The Business Research Company released a 2026 market report on hematocrit test devices. - The report puts the market at $4.91 billion in 2025 and $5.22 billion in 2026. - The report forecasts the market will reach $6.47 billion by 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to grow fastest during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

The details: - The report cites a 6.4% CAGR from 2025 to 2026. - The report cites a 5.5% CAGR from 2026 to 2030. - Growth drivers include rising prevalence of anemia and other blood disorders. - Additional drivers include expansion in hospital and laboratory diagnostic testing. - Demand is also rising from blood donor screening, emergency and trauma care, and greater awareness of hematocrit monitoring. - Future growth is expected to come from point-of-care diagnostics, chronic and lifestyle diseases, decentralized healthcare, home-based testing, diagnostic infrastructure spending and early disease detection. - Key trends include portable and handheld hematocrit meters, rapid blood parameter testing, more use in emergency and critical care, and routine screening for chronic disease management. - Hematocrit test devices are used for chronic illness monitoring, preoperative assessments, blood doping detection in sports, blood donor screening, emergency care and clinical research. - The report adds market attractiveness scoring, total addressable market analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics, key technologies analysis and updated graphics.

Between the lines: - Rising blood disorder incidence is the clearest near-term demand driver because it increases the need for routine hematocrit measurement. - The shift toward handheld and point-of-care devices suggests buyers want faster results outside central labs. - North America's lead suggests mature diagnostic adoption, while Asia-Pacific's growth points to expanding access and testing volume. - The report cites American Cancer Society estimates from January 2024 showing 62,770 new leukemia cases and 23,670 deaths in the United States, including about 20,800 acute myeloid leukemia cases and 11,220 deaths. - Those figures reinforce the clinical need for blood testing in diagnosis and disease management.

What's next: - The market is expected to keep expanding through 2030 as decentralized testing and preventive care gain ground. - Portable devices and emergency-use applications are likely to remain the fastest-moving product themes. - Regional growth in Asia-Pacific will be a key indicator of where new demand is emerging.

The bottom line: - Hematocrit testing is moving from a niche lab function toward broader, faster and more portable use across healthcare settings.